Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galapagos has announced that the company's service division, BioFocus DPI, will provide hit-finding services for multiple Allergan targets. Total contract value for Galapagos could reach up to E1.3 million over the next 12 months, contingent on the number of BioFocus DPI compounds screened.
Subscribe to our email newsletter
In this new collaboration, BioFocus DPI will provide assay development and high-throughput screening services for several Allergan targets. Furthermore, BioFocus DPI’s computational chemists plan to work together with Allergan to select compounds from the Allergan and BioFocus DPI compound libraries for screening against these targets.
Onno van de Stolpe, CEO of Galapagos, said: “We are pleased to sign another collaboration with Allergan. They are an important customer for BioFocus DPI’s biology business and having a satisfied customer coming back for more screening is gratifying.”